^
    3d
    An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Efficacy and Safety of mecapegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Breast Cancer (ChiCTR2600116027)
    P2, N=48, Not yet recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    HHPG-19K (mecapegfilgrastim)
    6d
    Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On-Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort. (PubMed, J Clin Apher)
    In conclusion, CTX + PEG-rhG-CSF + on-demand PXF is a highly effective salvage mobilization strategy for patients with initial HSC mobilization failure, yielding higher CD34+ cell counts with fewer aphereses and acceptable safety. With balanced advantages in efficacy, safety, and cost-effectiveness, the CTX + PEG-rhG-CSF + on-demand PXF regimen can be a preferred salvage option for ASCT candidates with prior mobilization failure.
    Retrospective data • Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • HHPG-19K (mecapegfilgrastim) • plerixafor
    4ms
    ANC-IIT-004: Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy (clinicaltrials.gov)
    P2, N=30, Recruiting, Affiliated Hospital of Nantong University
    New P2 trial
    |
    HHPG-19K (mecapegfilgrastim)
    6ms
    A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies (clinicaltrials.gov)
    P3, N=0, Withdrawn, Jiangsu HengRui Medicine Co., Ltd. | N=107 --> 0 | Trial completion date: Jun 2024 --> Jul 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: May 2024 --> Jul 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    HHPG-19K (mecapegfilgrastim)
    6ms
    Renaissance: Reverse Triple Negative Immune Resistant Breast Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Fudan University | N=30 --> 70 | Trial completion date: Mar 2023 --> Mar 2027 | Trial primary completion date: Dec 2022 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    AiRuiKa (camrelizumab) • trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • efavirenz • AiRuiLi (adebrelimab) • HHPG-19K (mecapegfilgrastim)
    9ms
    Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=132, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Jan 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • HHPG-19K (mecapegfilgrastim)
    9ms
    MA-ASCT-II-002: Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma (clinicaltrials.gov)
    P2, N=120, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial completion date: Sep 2024 --> Sep 2026 | Trial primary completion date: Mar 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • etoposide IV • HHPG-19K (mecapegfilgrastim)
    1year
    Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab) • HHPG-19K (mecapegfilgrastim)
    almost2years
    A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies (clinicaltrials.gov)
    P3, N=107, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    HHPG-19K (mecapegfilgrastim)
    over2years
    Application of Mecapegfilgrastim for Peripheral Blood Hematopoietic Stem Cell Mobilization in Patients With Hematologic Neoplasms and Analysis of Predictors for Poor Mobilization (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban)
    To evaluate the efficacy of applying mecapegfilgrastim for peripheral blood hematopoietic stem cell (PBSC) mobilization in patients with hematologic neoplasms, and to investigate the influencing factors of PBSC collection. Furthermore, combined mobilization with plerixafor was feasible and effective. Patients with leukemia or lymphoma, anemia, and WBC<32×10 L before stem cell collection have a high probability of PBSC collection failure.
    Journal
    |
    CD34 (CD34 molecule)
    |
    HHPG-19K (mecapegfilgrastim) • plerixafor
    almost3years
    Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=132, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    tamoxifen • fulvestrant • letrozole • exemestane • AiRuiKang (dalpiciclib) • HHPG-19K (mecapegfilgrastim)
    3years
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma (clinicaltrials.gov)
    P2, N=120, Recruiting, Qiu Lugui | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • etoposide IV • HHPG-19K (mecapegfilgrastim)